AAV9-induced Complement Activation ELISA

AAV9COMPLRUO

The AAV9-Induced Complement Activation ELISA is a Research Use Only (RUO) immunoassay developed to evaluate and characterize complement activation induced by adeno-associated virus 9 (AAV9) vectors in vitro.

  • Reliable, objective, and easy-to-interpret results
  • Results in just a few hours
  • Low inter-assay & intra-variability, demonstrating good reproducibility
  • Developed by our in-house experts to meet customer needs
  • Ready-to-use reagents for a streamlined workflow
  • Excellent specificity means clear results without false positives
Add to quote
AAV9-induced Complement Activation ELISA

Product Overview

AAV9-induced Complement Activation ELISA is a solid-phase enzyme immunoassay for evaluating complement activation triggered by AAV9 vectors.

This assay supports an expanded risk assessment profile of AAV gene therapy candidates, by specifically evaluating complement activation irrespective of the complement pathway (classical, lectin, and alternative) and sample-to-sample variability in a human-serum functional assay.

The AAV9-induced Complement Activation ELISA provides an ability to assess propensity to complement activation in subject samples in vitro. AAV9 particles are immobilized on a microtiter plate, enabling comprehensive capture of the entire process of AAV9-mediated complement activation, where complement activation is assessed via detection of deposited terminal complement complex (TCC). This includes interactions between AAV9 and anti-AAV9 reactive components, as well as the complement system, all within a single well from initiation to readout.

FOR RESEARCH USE ONLY

How it works

arrow
aav-compl-1

ELISA plate coated with immobilized vector

Wild-type vectors or your custom vector can be used.

aav-compl-2

Capture of Anti-AAV Binders

Anti-AAV antibodies and potential complement activators (e.g., immunoglobulins/C1q, MBL/ficolins, and C3b) are captured from a human serum sample under complement-suppressing conditions.

aav-compl-3

Complement activation

Following a washing step, the serum sample is reapplied in a complement-permissive buffer. If complement-activating binders are present, terminal pathway activity results in TCC deposition.

aav-compl-4

Detection

Detection is performed using an anti-TCC antibody, generating a signal proportional to the level of complement activation.

arrow

What's in the box?

  • One frame with microtiter wells (12x8)
  • 1.2 mL Positive control (PC)
  • 1.2 mL Negative control (NC)
  • 32 mL Diluent (Dil), red color
  • 35 mL Complement Activation Diluent (AAV Compl Dil)
  • 30 mL Wash solution, 30x concentrated
  • Serum, lyophilized
  • 15 mL Conjugate containing HRP-labelled antibody directed against TCC
  • 15 mL Substrate TMB
  • 15 mL Stop solution (0.5M H2SO4)
  • Sealing films

Please note: All reagents in the kit are ready to use except wash solution and lyophilized serum, with an optional dilution possible for the positive control. All reagents, except SERUM LYO, should be stored at 2–8°C, and are stable under these conditions until the kit’s expiration date. This also applies to the diluted wash solution. The SERUM LYO should be stored at ≤ -18°C or below. After reconstitution, the serum should be frozen at ≤ -70°C and may be thawed once.

Specifications

Product code AAV9COMPLRUO
Assay target AAV
Size 96 well
Technology ELISA
Detection system HRP/TMB read at 450 nm
Regulatory status Research Use Only
Assay time 4.5h

Documents